Medizinische Universität Innsbruck
Innsbruck, Austria
11 recruiting
Showing 1–20 of 22 trials
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche600 enrolled362 locationsNCT06819878
Recruiting
Phase 2Phase 3
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Electra Therapeutics Inc.156 enrolled40 locationsNCT05416307
Recruiting
Phase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche250 enrolled56 locationsNCT06847542
Recruiting
Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
Multiple System Atrophy
Ionis Pharmaceuticals, Inc.40 enrolled15 locationsNCT04165486
Recruiting
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
Friedreich Ataxia
Biogen300 enrolled14 locationsNCT06623890
Recruiting
Phase 3
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Leiomyosarcoma
PharmaMar450 enrolled97 locationsNCT06088290
Recruiting
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Hoffmann-La Roche850 enrolled59 locationsNCT06680817
Recruiting
Phase 3
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Glioblastoma, IDH-wildtypeMGMT-Methylated Glioblastoma
Vastra Gotaland Region200 enrolled20 locationsNCT06419946
Recruiting
Phase 3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
HER2-negative Breast CancerAdvanced Breast CancerER Positive Breast Cancer+1 more
MedSIR240 enrolled99 locationsNCT06382948
Recruiting
Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Gastric CancerGastroesophageal-junction Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Phase 3
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Alpha1-Antitrypsin Deficiency
Takeda160 enrolled89 locationsNCT05677971
Recruiting
Phase 3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
High-risk Large B-cell Lymphoma (LBCL)
Kite, A Gilead Company300 enrolled90 locationsNCT05605899
Recruiting
Phase 3
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Low-grade GliomaRapidly Accelerated Fibrosarcoma (RAF) Altered GliomaPediatric Low-grade Glioma
Day One Biopharmaceuticals, Inc.400 enrolled138 locationsNCT05566795
Recruiting
Phase 2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Type 1 Diabetes
SAb Biotherapeutics, Inc.159 enrolled65 locationsNCT07187531
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
Acute Myeloid Leukemia (AML)MDS/AML
University of Ulm50,000 enrolled94 locationsNCT01252485
Recruiting
Phase 3
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
High-grade Serous Ovarian Carcinoma (HGSOC)Fallopian Tube NeoplasmsOvarian Neoplasm Epithelial+3 more
Swiss GO Trial Group540 enrolled53 locationsNCT04111978
Recruiting
Safe and Timely Antithrombotic Removal (STAR) Registry
Blood Loss, SurgicalBlood Loss, PostoperativeHemorrhage, Surgical+1 more
CytoSorbents, Inc1,000 enrolled30 locationsNCT05077124
Recruiting
Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
Von Willebrand Disease
Baxalta now part of Shire31 enrolled46 locationsNCT02932618
Recruiting
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
Multiple Myeloma (MM)Chronic Lymphocytic Leukaemia (CLL)Secondary Immunodeficiency (SID)
Medical University Innsbruck120 enrolled5 locationsNCT06821880